The past, present, and (possible) future of serologic testing for lyme disease

Journal of Clinical Microbiology

Volumn 54, Issue 5, 2016, Pages 1191-1196

  Theel, Elitza S ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; BACTERIUM ANTIBODY;

ADAPTIVE IMMUNITY; ALGORITHM; ANTIBODY DETECTION; BACTERIAL TRANSMISSION; BORRELIA BURGDORFERI; CLINICAL FEATURE; CROSS REACTION; DIAGNOSTIC ACCURACY; ENZYME LINKED IMMUNOSORBENT ASSAY; HISTORY OF MEDICINE; HUMAN; IMMUNO POLYMERASE CHAIN REACTION; IMMUNOBLOTTING; INNATE IMMUNITY; LYME DISEASE; METABOLOMICS; MOLECULAR DIAGNOSTICS; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REVIEW; SENSITIVITY AND SPECIFICITY; SEROCONVERSION; SERODIAGNOSIS; TICK BORNE DISEASE; UNITED STATES; BLOOD; GENETICS; HISTORY; IMMUNOLOGY; METABOLISM; PROCEDURES; SEROLOGY; TRENDS;

ALGORITHMS; ANTIBODIES, BACTERIAL; BORRELIA BURGDORFERI; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; LYME DISEASE; METABOLOMICS; POLYMERASE CHAIN REACTION; SEROLOGIC TESTS; UNITED STATES;

EID: 84964977697     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.03394-15     Document Type: Review

References (29)

1. Hinckley AF, Connally NP, Meek JI, Johnson BJ, Kemperman MM, Feldman KA, White JL, Mead PS. 2014. Lyme disease testing by large commercial laboratories in the United States. Clin Infect Dis 59:676-681. http://dx.doi.org/10.1093/cid/ciu397.
2. Nelson CA, Saha S, Kugeler KJ, Delorey MJ, Shankar MB, Hinckley AF, Mead PS. 2015. Incidence of clinician-diagnosed Lyme disease, United States, 2005-2010. Emerg Infect Dis 21:1625-1631. http://dx.doi.org/10 .3201/eid2109.150417.
3. Aguero-Rosenfeld ME, Wang G, Schwartz I, Wormser GP. 2005. Diagnosis of Lyme borreliosis. Clin Microbiol Rev 18:484-509. http://dx.doi .org/10.1128/CMR.18.3.484-509.2005.
4. Alby K, Capraro GA. 2015. Alternatives to serologic testing for diagnosis of Lyme. Dis Clin Lab Med 35:815-825. http://dx.doi.org/10.1016/j.cll .2015.07.005.
5. Shapiro ED. 2014. Clinical practice. Lyme disease. N Engl J Med 370: 1724-1731. http://dx.doi.org/10.1056/NEJMcp1314325.
6. Aguero-Rosenfeld ME, Nowakowski J, Bittker S, Cooper D, Nadelman RB, Wormser GP. 1996. Evolution of the serologic response to Borrelia burgdorferi in treated patients with culture-confirmed erythema migrans. J Clin Microbiol 34:1-9.
7. Steere AC, McHugh G, Damle N, Sikand VK. 2008. Prospective study of serologic tests for Lyme disease. Clin Infect Dis 47:188-195. http://dx.doi .org/10.1086/589242.
8. Bakken LL, Case KL, Callister SM, Bourdeau NJ, Schell RF. 1992. Performance of 45 laboratories participating in a proficiency testing program for Lyme disease serology. JAMA 268:891-895. http://dx.doi.org/10 .1001/jama.1992.03490070073045.
9. Dressler F, Whalen JA, Reinhardt BN, Steere AC. 1993. Western blotting in the serodiagnosis of Lyme disease. J Infect Dis 167:392-400. http://dx .doi.org/10.1093/infdis/167.2.392.
10. Engstrom SM, Shoop E, Johnson RC. 1995. Immunoblot interpretation criteria for serodiagnosis of early Lyme disease. J Clin Microbiol 33:419-427.
11. Centers for Disease Control and Prevention. 1995. Recommendations for test performance and interpretation from the Second National Conference of Serologic Diagnosis of Lyme. MMWR Morb Mortal Wkly Rep 44:590-591.
12. Koedel U, Fingerle V, Pfister HW. 2015. Lyme neuroborreliosisepidemiology, diagnosis and management. Nat Rev Neurol 11:446-456. http://dx.doi.org/10.1038/nrneurol.2015.121.
13. Halperin JJ. 2015. Nervous system Lyme. Dis Clin Lab Med 35:779-795. http://dx.doi.org/10.1016/j.cll.2015.07.002.
14. Wormser GP, Schriefer M, Aguero-Rosenfeld ME, Levin A, Steere AC, Nadelman RB, Nowakowski J, Marques A, Johnson BJ, Dumler JS. 2013. Single-tier testing with the C6 peptide ELISA kit compared with two-tier testing for Lyme disease. Diagn Microbiol Infect Dis 75:9-15. http://dx.doi.org/10.1016/j.diagmicrobio.2012.09.003.
15. Chandra A, Latov N, Wormser GP, Marques AR, Alaedini A. 2011. Epitope mapping of antibodies to VlsE protein of Borrelia burgdorferi in post-Lyme disease syndrome. Clin Immunol 141:103-110. http://dx.doi .org/10.1016/j.clim.2011.06.005.
16. Ledue TB, Collins MF, Young J, Schriefer ME. 2008. Evaluation of the recombinant VlsE-based liaison chemiluminescence immunoassay for detection of Borrelia burgdorferi and diagnosis of Lyme disease. Clin Vaccine Immunol 15:1796-1804. http://dx.doi.org/10.1128/CVI.00195-08.
17. Branda JA, Linskey K, Kim YA, Steere AC, Ferraro MJ. 2011. Twotiered antibody testing for Lyme disease with use of 2 enzyme immunoassays, a whole-cell sonicate enzyme immunoassay followed by a VlsE C6 peptide enzyme immunoassay. Clin Infect Dis 53:541-547. http://dx.doi .org/10.1093/cid/cir464.
18. Fallon BA, Pavlicova M, Coffino SW, Brenner C. 2014. A comparison of Lyme disease serologic test results from 4 laboratories in patients with persistent symptoms after antibiotic treatment. Clin Infect Dis 59:1705-1710. http://dx.doi.org/10.1093/cid/ciu703.
19. Padula SJ, Dias F, Sampieri A, Craven RB, Ryan RW. 1994. Use of recombinant OspC from Borrelia burgdorferi for serodiagnosis of early Lyme disease. J Clin Microbiol 32:1733-1738.
20. Bacon RM, Biggerstaff BJ, Schriefer ME, Gilmore RD, Jr, Philipp MT, Steere AC, Wormser GP, Marques AR, Johnson BJ. 2003. Serodiagnosis of Lyme disease by kinetic enzyme-linked immunosorbent assay using recombinant VlsE1 or peptide antigens of Borrelia burgdorferi compared with 2-tiered testing using whole-cell lysates. J Infect Dis 187:1187-1199. http://dx.doi.org/10.1086/374395.
21. Arnaboldi PM, Seedarnee R, Sambir M, Callister SM, Imparato JA, Dattwyler RJ. 2013. Outer surface protein C peptide derived from Borrelia burgdorferi sensu stricto as a target for serodiagnosis of early Lyme disease. Clin Vaccine Immunol 20:474-481. http://dx.doi.org/10.1128/CVI .00608-12.
22. Norris SJ, Carter CJ, Howell JK, Barbour AG. 1992. Low-passageassociated proteins of Borrelia burgdorferi B31: characterization and molecular cloning of OspD, a surface-exposed, plasmid-encoded lipoprotein. Infect Immun 60:4662-4672.
23. Seriburi V, Ndukwe N, Chang Z, Cox ME, Wormser GP. 2012. High frequency of false positive IgM immunoblots for Borrelia burgdorferi in clinical practice. Clin Microbiol Infect 18:1236-1240. http://dx.doi.org /10.1111/j.1469-0691.2011.03749.x.
24. Binnicker MJ, Jespersen DJ, Harring JA, Rollins LO, Bryant SC, Beito EM. 2008. Evaluation of two commercial systems for automated processing, reading, and interpretation of Lyme borreliosis Western blots. J Clin Microbiol 46:2216-2221. http://dx.doi.org/10.1128/JCM.00200-08.
25. Wormser GP, Levin A, Soman S, Adenikinju O, Longo MV, Branda JA. 2013. Comparative cost-effectiveness of two-tiered testing strategies for serodiagnosis of Lyme disease with noncutaneous manifestations. J Clin Microbiol 51:4045-4049. http://dx.doi.org/10.1128/JCM .01853-13.
26. Lahey LJ, Panas MW, Mao R, Delanoy M, Flanagan JJ, Binder SR, Rebman AW, Montoya JG, Soloski MJ, Steere AC, Dattwyler RJ, Arnaboldi PM, Aucott JN, Robinson WH. 2015. Development of a multiantigen panel for improved detection of Borrelia burgdorferi infection in early Lyme disease. J Clin Microbiol 53:3834-3841. http://dx.doi.org/10 .1128/JCM.02111-15.
27. Halpern MD, Jain S, Jewett MW. 2013. Enhanced detection of host response antibodies to Borrelia burgdorferi using immuno-PCR. Clin Vaccine Immunol 20:350-357. http://dx.doi.org/10.1128/CVI.00630-12.
28. Niemeyer CM, Adler M, Wacker R. 2005. Immuno-PCR: high sensitivity detection of proteins by nucleic acid amplification. Trends Biotechnol 23:208-216. http://dx.doi.org/10.1016/j.tibtech.2005.02.006.
29. Molins CR, Ashton LV, Wormser GP, Hess AM, Delorey MJ, Mahapatra S, Schriefer ME, Belisle JT. 2015. Development of a metabolic biosignature for detection of early Lyme disease. Clin Infect Dis 60:1767-1775. http://dx.doi.org/10.1093/cid/civ185.